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Background: Pregnancy presents a unique situation for the management of asthma as it can alter the course of
asthma severity and its treatment, which in turn can affect pregnancy outcomes. Despite awareness of the
substantial adverse effects associated with asthma during pregnancy, little has been done to improve its
management and reduce associated perinatal morbidity and mortality. The aim of this randomized controlled trial
is to evaluate the clinical and cost effectiveness of an Antenatal Asthma Management Service.
Methods/design: Design: Multicentre, randomized controlled trial.
Inclusion criteria: Women with physician diagnosed asthma, which is not currently in remission, who are less than 20
weeks gestation with a singleton pregnancy and do not have a chronic medical condition.
Trial entry and randomization: Eligible women with asthma, stratified by treatment site, disease severity and parity, will
be randomized into either the ‘Standard Care Group’ or the ‘Intervention Group’.
Study groups: Both groups will be followed prospectively throughout pregnancy. Women in the ‘Standard Care Group’
will receive routine obstetric care reflecting current clinical practice in Australian hospitals. Women in the ‘Intervention
Group’ will receive additional care through the nurse-led Antenatal Asthma Management Service, based in the
antenatal outpatient clinic. Women will receive asthma education with a full assessment of their asthma at 18, 24, 30
and 36 weeks gestation. Each antenatal visit will include a 60 min session where asthma management skills are
assessed including: medication adherence and knowledge, inhaler device technique, recognition of asthma
deterioration and possession of a written asthma action plan. Furthermore, subjects will receive education about asthma
control and management skills including trigger avoidance and smoking cessation counseling when appropriate.
Primary study outcome: Asthma exacerbations during pregnancy.
Sample size: A sample size of 378 women will be sufficient to show an absolute reduction in asthma exacerbations during
pregnancy of 20% (alpha 0.05 two-tailed, 90% power, 5% loss to follow-up).
Discussion: The integration of an asthma education program within the antenatal clinic setting has the significant
potential to improve the participation of pregnant women in the self-management of their asthma, reduce asthma
exacerbations and improve perinatal health outcomes.
Trial registration: ACTRN12613000244707
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Pregnancy presents a unique situation for the manage-
ment of asthma as it can alter the course of asthma se-
verity and its treatment, which in turn can affect
pregnancy outcomes. Despite awareness of the substan-
tial adverse effects associated with asthma during preg-
nancy, little has been done to improve its management
and reduce associated perinatal morbidity and mortal-
ity. Asthma is the most prevalent complication to affect
human pregnancy in Australia, affecting an estimated
12% of pregnant women, or 36,000 pregnancies each
year [1]. The significance of asthma in pregnancy is
highlighted in a recent meta-analysis, demonstrating
clear associations between asthma in pregnancy and ad-
verse perinatal outcomes, including increased risk of
low birth weight (RR 1.46; 1.22-1.75), small-for-
gestational age (RR 1.22; 1.14-1.31), preterm delivery
(RR 1.41; 1.22-1.61) and pre-eclampsia (RR 1.54; 1.32-
1.81) [2]. The adverse effects of asthma in pregnancy
are related to asthma severity and the intensity of
treatment [3-5]. Studies of women with well controlled
asthma, which involves the regular use of inhaled corti-
costeroids (ICS) to inhibit inflammatory mechanisms at
a systemic level, seldom demonstrate adverse effects on
fetal outcome [3,6]. In contrast, regular use of oral cor-
ticosteroids (OCS), used in the management of acute
asthma exacerbations and poorly controlled asthma
during pregnancy, has been associated with an in-
creased incidence of low birth weight babies and pre-
term delivery [7]. A number of studies have examined
the effects of maternal asthma during pregnancy, in the
presence and absence of ICS treatment, on placental
function and fetal development. These studies have
demonstrated that use of ICS for the treatment of
asthma did not affect fetal growth and that maternal
asthma without treatment had a greater impact on the
fetus and placenta [8]. Furthermore, acute asthma exac-
erbations were identified as the most significant event
to affect fetal morbidity and mortality in pregnancies
complicated by asthma [9,10]. That is, poor asthma
control is a greater risk factor for an adverse outcome
during pregnancy than ICS use [10]. In contrast, evi-
dence demonstrates little or no increased risk of adverse
maternal or fetal complications in situations where
asthma is well controlled throughout pregnancy [6,11].
These findings point to the fact that optimization of
asthma management and asthma control is key to im-
proving perinatal outcomes. As such, pregnancy repre-
sents a significant indication to optimize therapy and
maximize lung function in order to reduce the risk of
acute exacerbation and resultant adverse health out-
comes. This study will address these issues through the
development and evaluation of cost effective ways of
improving antenatal management of asthma.Current care of pregnant women with asthma
Clear guidelines exist for the management of asthma
during pregnancy, which involves managing asthma medi-
cations in pregnant women in the same manner as a non-
pregnant adult [12]. This relates to assessing asthma
control and adjusting inhaled medications accordingly at
regular intervals during pregnancy. The significant burden
associated with asthma is highlighted through National
Health Surveys which identified that approximately 12% of
women of childbearing age report having current asthma
[1,13]. While no studies have directly assessed the preva-
lence of asthma amongst pregnant women in Australia,
prospective cohort studies [14] and antenatal surveys [15]
undertaken amongst pregnant women have identified a
similar prevalence of approximately 12-13%. Despite this
estimated high prevalence, only 6% of pregnancies are re-
ported to be affected by asthma in Australian perinatal sta-
tistics collections [16]. This apparent under reporting of
asthma prevalence could be a result of the fact that asthma
is not well recognized as a significant co-morbidity of preg-
nancy and has the potential to result in reduced capacity to
manage the disease during pregnancy.
Currently, there is no structured approach in which
asthma in pregnancy is managed. While a small number
of women with very severe asthma receive monitoring
during pregnancy in the antenatal clinic with respiratory
physician support, treatment is often limited to women
self-managing their asthma with support from their family
doctor. Current asthma management appears to be fo-
cused on a reactive, rather than proactive, approach, which
is demonstrated by the fact that only 15% of pregnant
women with asthma involved in a prospective study had
an asthma action plan [17]. Therefore, there is clear evi-
dence that current care of pregnant asthmatic women
could be significantly improved and there is an immediate
need for evidence based approaches for improving clinical
practice.
Asthma exacerbations during pregnancy are associated
with an adverse outcome
Exacerbations are a key feature of asthma and ideal target
for improving asthma control and related outcomes. The
definition of an asthma exacerbation is any asthma related
event that involved one or more of the following; a hos-
pital admission, an unscheduled doctor visit, a course of
oral steroids or an increase in medication use. A system-
atic review identified that 6% of asthmatic women are hos-
pitalized for a severe exacerbation during pregnancy, and
that 20% have a severe exacerbation during pregnancy re-
quiring medical intervention [7]. Furthermore, evidence
demonstrates that the rates of exacerbations during preg-
nancy increases according to asthma severity [18]. Among
those with mild, moderate and severe asthma the exacer-
bation rates have been reported as 13%, 26% and 52%,
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leading to hospitalization were 2%, 7% and 27% [18]. Rely-
ing solely on asthma severity, however, can be misleading
as asthma can worsen during pregnancy regardless of ma-
ternal pre-pregnancy severity [7,10]. That is to say; an
asthmatic woman can be a mild asthmatic pre-pregnancy
and become a severe asthmatic during pregnancy. In
addition, the severity of an exacerbation does not always
reflect underlying asthma severity (i.e. women with mild
asthma can have a severe exacerbation). This means it is
difficult to identify accurately those women at risk of
worsening asthma during pregnancy.
Risk factors for exacerbations during pregnancy
While exacerbations can occur at any time during preg-
nancy, evidence from a prospective cohort of women with
asthma identified that exacerbations were most likely in
the second and third trimesters between weeks 17 and 34,
with a peak incidence around 25 weeks gestation [10]. Risk
factors associated with asthma exacerbations during preg-
nancy include respiratory viral infections and a lack of ap-
propriate treatment with inhaled corticosteroids (ICS).
Asthmatics appear to be more susceptible to respiratory
tract infection during pregnancy and also have an in-
creased risk of community-acquired pneumonia [19]. This
suggests that the combination of asthma and pregnancy
may significantly increase the risk of infection and may re-
sult in acute asthma exacerbations during pregnancy. Im-
provements in asthma management that address these
issues and reduce exacerbation rates on a population basis
are needed.
Treatment of asthma and asthma exacerbations
during pregnancy
Pregnancy has a unique effect on decisions around asthma
control and management. Despite guidelines recommend-
ing the continuing of usual asthma medications during
pregnancy, it is not uncommon for women to cease their
medications, with or without consultation with their doc-
tors [20]. These decisions may be driven by a perceived
lack of need to continue their medications, a lack of sup-
port and guidance from health professionals regarding how
to manage their asthma medications and/or concerns re-
garding the safety of asthma medications during pregnancy
[21]. These concerns may not be unique to women them-
selves, as a previous survey demonstrated that in situations
where asthma was well controlled, over 25% of family phy-
sicians would instruct their pregnant patients to decrease
or discontinue asthma medication during pregnancy, des-
pite the potential to negatively impact on subsequent
asthma control [22]. Furthermore, a study conducted in
the US found that pregnant women with an asthma ex-
acerbation were significantly less likely to be given oral ste-
roids either in the emergency department or on dischargefrom hospital than non-pregnant asthmatic women (50.8%
vs. 72.4%) [23]. Subsequently, pregnant asthmatic women
were three times more likely to report an on-going asthma
exacerbation following discharge when compared with
non-pregnant asthmatic women [23]. The lack of treat-
ment of an exacerbation during pregnancy can severely
compromise the fetus by reducing the oxygen supply to
the utero-placental unit and has a more significant impact
on the fetus than the medication itself [24]. Daily ICS use
has previously been identified as a safe medical approach
to controlling asthma during pregnancy and reducing the
risk of exacerbation [24-27]. The uncertainty, concerns and
variability in practice surrounding medication use and
asthma control during pregnancy emphasizes the key need
for a dedicated Antenatal Asthma Management Service.
Existing evidence on the provision of asthma self-
management skills and education during pregnancy
Previous research undertaken by the research team has
demonstrated that asthma education combined with an
asthma action plan administered in the antenatal clinic by
a respiratory nurse is associated with a significant im-
provement in birth weight relative to women who did not
use an action plan during pregnancy [17], and may reduce
the risk of exacerbations as a result of improved asthma
control.
In this study asthmatic women were prospectively re-
cruited at their first antenatal visit and attended a nurse-
led asthma management service at the antenatal clinic at
20 and 33 weeks gestation (n = 211) [17]. Lung function,
asthma symptoms, compliance with medications, medica-
tion knowledge and inhaler technique were assessed.
Women were given a written asthma action plan and edu-
cated in peak flow monitoring for home use. At the first
visit, the majority of women were identified as having poor
asthma self management skills and knowledge, regardless
of the severity of their disease [17]. Limitations of this
study were that the service was not assessed as part of a
RCT (i.e. all women received intervention) and small sam-
ple size, limiting the ability to effectively assess the clinical
and cost effectiveness of the intervention.
As a follow-up to this study a RCT was undertaken to in-
vestigate the clinical use of exhaled fraction of nitric oxide
(FENO), as a measure of inflammation, to adjust asthma
management during pregnancy. Use of FENO to adjust
asthma treatment was associated with a significant reduc-
tion in the exacerbation rate during pregnancy (0.288 vs.
0.615; p = 0.001) and a reduction in neonatal hospitaliza-
tions (8% vs. 17%; p = 0.046) [28]. The major limitation of
this trial, however, was that only non-smokers were en-
rolled in the study as cigarette use inhibits exhaled NO
production in asthmatics and therefore can significantly
mask the interpretation of NO data [29]. This significantly
restricts the generalisability of this approach given the high
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pregnancy (reported to be at least 34% in one Australian
cohort study) [14]. The applicability of FENO to routine
clinical settings is further limited due to issues around ex-
pense and accessibility. In addition, as all women in the
study attended a respiratory nurse-led asthma manage-
ment service, this limits the ability to adequately assess the
clinical and cost effectiveness of this intervention.
While these two studies demonstrate the feasibility of
providing an Asthma Management Service in the ante-
natal setting and the potential significant benefits it may
achieve, an RCT is the only rigorous approach to truly de-
termine the clinical and cost effectiveness of a nurse-led
Antenatal Asthma Management Service versus standard
clinical care.
Summary
Given the scarcity of available health resources, the
evaluation of the clinical and cost effectiveness of this
intervention is important to establish whether our pre-
vious research findings can be translated into an effective
clinical practice integrated with routine antenatal services.
The proposed model makes use of specially trained respira-
tory nurses to deliver an Antenatal Asthma Management
Service. The use of nurse-led clinics can facilitate specialist
intervention at times of identified patient need, while nurs-
ing health practice allows for the introduction of preventa-
tive health practices to patients which cannot always be
introduced by doctors due to limitations on time. The in-
tegration of an adapted model of an asthma education
program within the antenatal clinic setting has the signifi-
cant potential to improve the participation rate of preg-
nant women in the self-management of their asthma,
reduce asthma exacerbations and thus improve perinatal
health outcomes. It will also integrate well with a shared
care model where asthma education occurs as part of the
antenatal visits to the hospital with communication with
the primary care physician and specialist physician. Posi-
tive outcomes will demonstrate the potential value of
nurse led interventions, leading to closer consideration of
other clinical conditions in which similar nurse-led initia-
tives could be evaluated and implemented.
Aims and objectives of this trial
The aim of this randomized controlled trial is to evalu-
ate the clinical and cost effectiveness of an Antenatal
Asthma Management Service.
Hypothesis
The provision of a nurse-led Antenatal Asthma Man-
agement Service (AAMS) is a cost effective interven-
tion to improve asthma management and maternal
health and well being and reduce the incidence of
asthma exacerbations.Methods/design
Ethics statement
Ethics approval was granted by the Human Research Ethics
Committee of The Queen Elizabeth Hospital, Lyell
McEwin Hospital and Modbury Hospital in Adelaide,
South Australia (HREC/12/TQEHLMH/73).
Study design
Multicentre parallel-group randomized controlled trial.
Setting
This study will involve two public hospital antenatal
clinics which account for 40% of all births in South
Australia, Australia. These hospitals are the Lyell McEwin
Hospital (LMH) and Flinders Medical Centre (FMC). A
clinical study has been running at the LMH throughout
2012 to demonstrate the feasibility of implementing an
Antenatal Asthma Management Service. During this
period approximately 40 referrals have been received each
month from the antenatal outpatient clinic for women
with asthma. This represents an estimated prevalence of
asthma in this population of 14%. This high prevalence is
likely due to the fact that more than 70% of women with
asthma use public health care and that the prevalence of
asthma is higher among those with lower socioeconomic
status [14], reflective of the area in which LMH is situated.
In comparison to the LMH, FMC is situated in a region of
higher SES than LMH (SA Health Atlas). This will enable
the clinical and cost-effectiveness of the service to be in-
vestigated in two diverse settings, as previous research has
identified that SES is a significant risk factor for outcomes
related to maternal asthma [30].
Recruitment
All pregnant women with asthma attending their first
booking visit (approximately 12 weeks gestation) at the
antenatal outpatient clinic will be identified by the attend-
ing midwife. The midwife will ask several questions to es-
tablish the presence of asthma including “have you been
told by a doctor that you have asthma? As well as “Have
you used any asthma medications in the last year such as
salbutamol or a preventer?” Women identified as having
asthma will be referred by the attending midwife and will
be subsequently interviewed by a research midwife associ-
ated with this study who will explain the project to them
by providing both written and verbal information.
To be eligible, participants must be less than 20 weeks
gestation at the time of recruitment, have asthma which
has been previously diagnosed by a doctor and is not cur-
rently in remission (remission defined as no asthma symp-
toms and no use of asthma medications in previous year),
aged 18–45 years, expected to give birth to a singleton
and be able to speak English. Participants will be excluded
from the study if they have previously participated in an
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chronic medical condition (i.e. diabetes, hypertension, car-
diac disease, HIV/hepatitis, renal disease, haematology dis-
order (i.e. thalassaemia, thrombophilia), thyroid disorder,
psychiatric disease requiring therapy with antidepressant
or antipsychotic, epilepsy).
Data collection at trial entry
Eligible women who agree to take part in the study and
sign an informed consent, will be asked to complete a
baseline assessment of their asthma. Participants will be
asked routine questions to determine their asthma severity
in accordance with the National Asthma Council Asthma
Management Handbook classifications [12]. This classifi-
cation takes into account asthma medications, symptoms
and spirometry results to reach an approximate baseline
asthma severity classification in women with treated
asthma. Women will be classified as intermittent, mild,
moderate or severe. In addition, their asthma control will
be assessed by administering the Juniper Asthma Control
Questionnaire (ACQ) (how many days in the past week
the subject has been affected by night time symptoms,
morning symptoms, activity limitation due to asthma as
well as frequency of β2-agonist use) [17]. Forced expira-
tory volume at one second (FEV1) and forced vital cap-
acity (FVC) will be measured by an Easy One spirometer
before and after administration of salbutamol in all sub-
jects. FEV1% predicted will be calculated based on the pa-
tients age, ethnicity and height using the equations of
Gore et al. [31]. Further data will be collected using a cold
and flu questionnaire to determine the impact of illness
on current asthma control. These validated question-
naires, in addition to a structured data collection form,
will be used to determine current asthma therapy and
control, current asthma triggers and co-morbidity and
past history including frequency of oral corticosteroid use
and previous hospital admissions for asthma. In addition,
data will be collected on smoking (direct and passive ex-
posure), Quality of Life (Mini Asthma Quality of Life
Questionnaire [32]) and psychological variables using the
Perceived Control of Asthma Questionnaire [33], Brief
Illness Perception Questionnaire [34], Medical Adherence
Report Scale-Asthma [35], Patient-Clinician Communica-
tion Questionnaire [36], Beliefs About Medicines Ques-
tionnaire [37], Teratogenic Risk Perception Questionnaire
[38], and a purpose designed Asthma Knowledge Ques-
tionnaire. For all participants blood will be drawn for total
IgE and RAST testing to assess atopy.Study groups and management
Eligible women with asthma will be randomized into
one of two study groups: either the ‘Standard Care
Group’ or the ‘Intervention Group’.Randomization
After the baseline assessment of asthma at 18 weeks gesta-
tion, women will be randomised to receive either standard
care or nurse-led asthma management during pregnancy
by contacting the central telephone randomization service
at the University of Adelaide. The telephone randomization
service will use a randomization schedule with balanced
variable blocks, prepared by an investigator not involved
with recruitment or clinical care. Stratification will be
undertaken according to treatment site, parity and asthma
severity. During the randomization call, eligibility will be
checked and information collected to enable stratification
and to assist in follow-up.
Treatment schedules
Standard care group
Standard care will be as outlined in the SA Perinatal
Practice Guideline for the treatment of asthma during
pregnancy (Available from www.sahealth.sa.gov.au). This
involves women with asthma self managing their disease
during pregnancy and seeking guidance for asthma man-
agement when required from a midwife, obstetrician, re-
spiratory physician or GP. Some women in this group will
already be managed by a respiratory specialist and this will
be continued. While women receiving standard care
will be followed-up at exactly the same time points as
those in the intervention group, no formal attentional
control will be utilized. Notably, while some researchers
advocate for the use of attention controls there is, at
this point in time, a significant lack of understanding
regarding what constitutes an appropriate attention
control group. There is also a lack of understanding re-
garding the potential benefits (or biases) associated with
the use of an attention control, limiting its ability to be
utilized in this setting [39].
Intervention group
The intervention group will receive care through the
nurse-led Antenatal Asthma Management Service, based
in the antenatal outpatient clinic. The Antenatal Asthma
Management Service will be led by a respiratory nurse
with qualifications in asthma management and education
and spirometry. The details of the methodology to be used
for nurse-led respiratory care in our study have been pre-
viously published [17]. All asthmatic women will receive
asthma education with a full assessment of their asthma
at 18, 24, 30 and 36 weeks gestation conducted by a
respiratory nurse. Each antenatal visit will include a
60 min session where asthma management skills are
assessed including: medication adherence and know-
ledge, inhaler device technique, recognition of asthma
deterioration and possession of a written asthma action
plan [17]. In addition, subjects will receive education
about asthma control and management skills including
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appropriate [17]. While it is standard antenatal care for all
pregnant women to complete a smoking questionnaire at
their first booking visit and be encouraged to quit smok-
ing, an additional key component of the Antenatal Asthma
Management Service will be in providing additional coun-
seling on the importance of smoking cessation in relation
to their asthma and the health of their baby. Women will
be provided with information on the benefits of smoking
cessation and direct referrals will be made to QuitSA for
cessation support.
During the first visit at 18 weeks gestation, all subjects
will be provided with an individualized written asthma ac-
tion plan, which has been developed according to evidence
based principles by the asthma educator using a standard-
ized template following National Asthma Council recom-
mendations [12]. In addition, current asthma management
therapies will be evaluated and recommendations regard-
ing optimal therapy will be made. If women are identified
at their first antenatal visit as having unstable asthma, as
determined by the Juniper Asthma Control Questionnaire
(ACQ) score of >1.5 a recommendation will be made for
step-up therapy in accordance with well-established clin-
ical guidelines and previous studies [28]. If inhaled corti-
costeroids need to be prescribed an on-call respiratory
physician will be contacted. A detailed asthma manage-
ment report, including asthma action plan and recom-
mended changes in therapy if required, will be forwarded
to the participant’s preferred family physician (i.e. gen-
eral practitioner) who will review each action plan and
assess the appropriateness of recommended changes in
therapy. This preferred provider will be the lead clinician
responsible for her asthma management during pregnancy.
All recommendations made through the Antenatal
Asthma Management Service will be recorded and
followed-up to determine their outcome (i.e. acceptance
of recommendation).
During subsequent visits to the Antenatal Asthma
Management Service, the respiratory nurse will con-
tinually review asthma control and management plans.
Subjects assessed as having poor asthma control (ACQ>
1.5) or experiencing a current exacerbation will be referred
to their usual family physician in the community or respira-
tory physician in the hospital for appropriate review.
During antenatal appointments urgent medical review
will be available for patients with an acute exacerbation.
The respiratory nurse and designated family physician
and/or respiratory physician will collaborate closely on ap-
propriate step-up therapy for the participant.
Between visits, participants will be encouraged to follow
their asthma action plan closely and see their family doctor
if their asthma worsens. Those subjects who also attend
specialist respiratory clinics will also have information for-
warded to their physician for reference. Subjects will beencouraged to maintain these specialist visits. During the
study, care received for asthma management from a GP, ob-
stetrician or respiratory specialist will be noted.
A flow chart of care is depicted in Figure 1.
Data collection
All women will receive a baseline assessment of their
asthma as previously described. Data will be collected on
participants receiving standard care by a trained research
midwife and those receiving the intervention by the re-
spiratory nurse at 24, 30 and 36 weeks gestation. This will
be undertaken using a structured data collection tool. At
each time point asthma control will be assessed using the
ACQ and spirometry. Further data will be collected using
a cold and flu questionnaire to determine the impact of ill-
ness on current asthma control. A current pregnancy re-
lated history will be collected by research midwife
interview for any unscheduled doctor visits due to asthma,
an increased use of inhaled glucocorticoid, any visits to
the Emergency department and any hospital admissions
related to asthma, occurring since the previous visit. These
data will be used to determine the number and timing of
any asthma exacerbations occurring during the study.
Data on asthma medication use will be utilized to calculate
a cumulative ICS dose for each trimester. In addition,
women will be asked to complete a questionnaire relating
to smoking (direct and passive), and asthma related quality
of life. Furthermore, data will be collected on the level of
care received for asthma management from a GP, obstetri-
cian or respiratory specialist (i.e. type and number of
visits). Women receiving care through the Antental
Asthma Management Service will have additional data
collected on psychological variables as outlined in the sec-
tion on data collection at trial entry (i.e. Perceived Control
of Asthma Questionnaire [33]). Medicare Benefits Scheme
(MBS) and Pharmaceutical Benefits Scheme (PBS) data
relating to medical care and medication use throughout
pregnancy will be accessed by participant consent. For
all women, data on pregnancy complications, labour,




The primary outcomes in this study will be the percentage
of women that experienced exacerbations during preg-
nancy (moderate and severe) defined as events for which
the participant sought medical attention (i.e. an unsched-
uled visit to a doctor, presentation to the emergency de-
partment room or admission to hospital, or when oral
corticosteroids were used for treatment of asthma). Based
on previous research undertaken by our research group it
is hypothesised that participation in the Antenatal Asthma
Management Service will result in a 20% reduction
IF ACQ 1.5 IF ACQ 1.5
IF ACQ 1.5IF ACQ 1.5




All pregnant asthmatic women identified at antenatal booking visit (12-14 
weeks gestation) are assessed for eligibility and consented into study
Baseline assessment of asthma at 18 weeks
- Asthma history and assessment
- Asthma severity and control
- Spirometry
Randomisation by telephone system
Initial Visit
@ 18 weeks gestation
- Asthma education session
- Evaluation of asthma control and management
- Development of Asthma Action Plan
- Detailed asthma management report written
Antenatal Asthma Management Service
Follow-up Visits
@ 24, 30 & 36 weeks gestation
- Reinforcement of asthma knowledge
- Re-evaluation of asthma control and management
- Revision of Asthma Action Plan (If necessary)
Referral to GP or respiratory physician
- No change in asthma therapy required
- Confirm Asthma Action Plan
Referral to GP or respiratory physician
- Assess appropriateness of step-up therapy
- Confirm Asthma Action Plan
No further referral required
- Follow Asthma Action Plan
Referral to GP or respiratory physician
- Assess appropriateness of step-up therapy
- Reassess Asthma Action Plan
6 Month Follow-up of all children
Delivery Outcomes Recorded
Assessment of asthma 
control by research 
midwife at 18, 24, 30 
& 36 weeks gestation
Standard antenatal outpatient 
appointments with routine 
evaluation of asthma according 
to SA Perinatal Practice 
Guidelines
Figure 1 AAMS study design.
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pregnancy in the intervention group compared to the con-
trol group [28].
Secondary study outcomes
For the mother, the secondary outcomes will be:
Asthma related variables defined as; ACQ score and
FEV1 throughout gestation, asthma related quality of life,
perceived control of asthma, medication adherence and
asthma knowledge.
Adverse health outcomes defined as; hypertensive dis-
orders of pregnancy, antepartum haemorrhage, gesta-
tional diabetes, preterm labour, need for antenatal
hospitalization, weight gain during pregnancy, chor-
ioamnionitis requiring antibiotics during labour, length
of postnatal hospital stay, use of postnatal antiobitiocs
and postpartum haemorrhage (≥500 mls) and emergency
caesarean section.
For the infant/child, the secondary study outcomes
will be:Cases of infant morbidity defined as; Gestational age at
delivery (determined by date of the last menstrual period
and 18 week ultrasound), Preterm delivery (<37 weeks
gestation), birth weight, birth length, head circumference
IUGR (defined as those babies whose birth weight was less
than or equal to the 5th centile), birth-weight-percentile
(calculated using www.gestation.net), Apgar scores, con-
genital malformations, admission to neonatal intensive
care unit or special care nursery and stillbirth.
Sample size
In recognition of potential differences in the implementa-
tion and successfulness of the intervention across two dis-
tinct treatment sites, the sample size was calculated to
ensure adequate statistical power within each treatment
site. The total sample size of 378 pregnant women at base-
line (189 in each group and each treatment site) was de-
termined by power calculations (using 90% power and a
5% level of significance) using the primary outcomes of
difference in exacerbation rate between treatment groups.
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45% to 25%) in the incidence of asthma exacerbations as
both achievable and clinically significant. The calculated
sample size includes an estimated 15% loss to follow-up.
We estimate there are at least 360 pregnancies complicated
by asthma each year at each hospital and we will need to
recruit 27% (n = 95 per site each year) of women presenting
to the antenatal clinic per year to complete study recruit-
ment over 2 years.
Statistical analysis
Baseline characteristics of all randomized women will
be compared descriptively between the study groups.
Outcome comparisons will be made according to the
treatment allocation at randomization on an ‘intention
to treat’ basis. For the primary outcome, the difference
in exacerbation rates between groups will be compared
using a Poisson regression model. This will enable cal-
culation of the incident rate ratio and associated 95%
confidence interval.
For secondary outcomes, discrete outcomes (i.e. low
birth weight) will be analysed using log binomial regres-
sion and continuous outcomes (i.e. birth weight, gesta-
tional age) analysed using linear regression. Continuous
variables with repeated measurements (i.e. questionnaire
results, ACQ score) will be analysed using a generalized
linear mixed model (GLMM) with a random intercept
for individuals to account for repeated measurements.
Planned sub-analyses will be undertaken to assess
the effects of asthma control, FEV1, asthma medication
use, cumulative ICS exposure, asthma knowledge and
medication adherence, on the primary and secondary
outcomes. SPSS Version 20 (SPSS Inc., Chicago, IL,
USA). and Stata IC 11.1 (Stata, College Station, TX,
USA) will be used for analyses. Statistical significance
will be assessed at the 0.05 level using a two-sided
comparative test.
Cost effectiveness
A cost-effectiveness analysis will incorporate costs of pro-
viding standard care and the Antenatal Asthma Manage-
ment Service, costs and quality of life effects associated
with asthma-related adverse events, including mild and se-
vere exacerbations, and fetal outcomes. This will deter-
mine whether, and under what circumstances, the
provision of an Antenatal Asthma Management Service
would be cost-effective. The economic evaluation will be
performed from a societal and health care perspective.
Direct medical costs (i.e. costs of intervention, asthma re-
lated consultations) as well as indirect costs (i.e. asthma
related quality of life) will be taken into account. Relevant
fixed unit costs associated with the delivery of standard
care and the Antenatal Asthma Management Service
intervention (i.e. costs of running the antenatal clinic,visits with respiratory nurse and respiratory specialist/pre-
ferred GP) will be estimated and allocated proportionally
across the patients in the respective trial arms.
Additional costs associated with respiratory related
health-care (i.e. asthma exacerbations, medication treat-
ment costs), antenatal related health-care (i.e. preg-
nancy complications, medication treatment costs) and
neonatal related health-care (i.e. admission to NICU) will
be identified to determine a total cost estimate for the
mother and child. We will obtain consent from patients to
access all Medicare Benefits Schedule (MBS) (i.e. GP con-
sultations) and Pharmaceutical Benefits Schedule (PBS) (i.e.
medication costs) data to collate accurate data on unit costs
associated with receiving either intervention during preg-
nancy. We will also obtain consent to access public hospital
data, and so will capture emergency, outpatient, and in-
patient encounters and the relevant unit costs associated
with these encounters.
Missing cost data, for example, from patients who did
not consent to access to their MBS, PBS, and public hos-
pital data will be imputed using the Multiple Imputation
using Chained Equations (MICE) approach.
To analyse long-term cost-effectiveness, extrapolation
models for adverse neonatal outcomes (e.g. low birth
weight and IUGR) will be developed, based on existing lit-
erature. A structured review of the literature will inform
the costs and consequences (i.e. effects on Quality of Life)
of adverse neonatal outcomes identified, which will be
synthesised to model the short- and longer-term add-
itional health-related events that a cohort of such babies
would be expected to experience over their lifetime, or
over a defined time horizon (e.g. 20 years). Similar lifetime
extrapolation models have previously been developed in
the areas of thalassaemia and sickle cell disease [40,41].
The resulting dataset will contain estimates of the short-
and long-term costs and outcomes for all patients (mother
and child), and will be analysed to estimate the expected
costs and outcomes in the patient cohorts receiving the
different levels of care.
To facilitate cost-effectiveness comparisons with in-
terventions across other disease areas, outcomes for
both mothers and children will be converted to quality
adjusted life years (QALYs). Utility weights for mothers
will be derived from responses to the AQoL [42], for
which an Australian-based algorithm is available. The ex-
trapolation models for fetal outcomes will incorporate
literature-based health state utility weights for events in-
cluded in the model to estimate QALYs gains in this popu-
lation. The within trial analysis will report the costs and
varied consequences (i.e. effects on mother and baby) of
the different interventions. To inform comparisons with
the cost-effectiveness of interventions across the health
care system, the data from the study will be combined
with the extrapolation models to estimate the expected
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Antenatal Asthma Management Service.
Every trial participant will have an estimated lifetime
cost, and QALY value. If imbalances in baseline charac-
teristics across the treatment groups are observed, pro-
pensity weighted generalized linear models will be used
to generate adjusted mean cost and QALY estimates for
each treatment group. In the absence of imbalance, the
mean cost and QALY estimates in each group will in-
form mean incremental cost-effectiveness ratios, and in-
cremental net monetary benefits.
Uncertainty will be represented using deterministic
and probabilistic (bootstrapped) sensitivity analyses.
The probabilistic analysis will inform credible intervals
around the incremental cost-effectiveness ratios and
cost-effectiveness acceptability curves based on alterna-
tive assumed monetary equivalent values of a QALY.
Trial management
An independent data monitoring committee will be estab-
lished, with terms of reference jointly defined between trial
investigators and the independent committee members
prior to study commencement. A multidisciplinary adverse
events committee blinded to treatment allocation will re-
view the cause of death for all maternal and infant deaths.
These data will be made available to the independent data
monitoring committee. In addition, the committee will
conduct an interim analysis midway through the trial after
the inclusion of 189 women. They will be unaware of treat-
ment allocation when they judge data on effectiveness and
safety and will compare these against the stopping rules
outlined in the terms of reference. All study investigators
have agreed to meet on a monthly basis to monitor trial
progress and procedure. A respiratory physician who spe-
cialises in asthma management will provide a quality assur-
ance review of the asthma management clinic every
6 months at both sites.
Discussion
The clinical and cost effectiveness of an Antenatal
Asthma Management Service has not been rigorously
evaluated to date through a randomized controlled
trial. Asthma is the most prevalent chronic medical
condition to affect human pregnancy and is expected
to increase in coming years, representing a significant
burden for the healthcare system. This associated bur-
den lies in coping with the increasing demands of car-
ing for pregnant women with asthma and in dealing
with its associated adverse effects on perinatal health
outcomes.
The need for, and potential of, an individualized re-
view of asthma management during pregnancy has
been well demonstrated in previous research under-
taken through this research group [17]. Given finiteresources, however, it is unlikely that existing models
of practice could cope with the increased requirements
of providing an asthma management service as out-
lined in this protocol, highlighting the importance of
this clinical and cost effectiveness analysis.
The provision of an Antenatal Asthma Management
Service conducted by a respiratory nurse provides an
alternative approach for the introduction of education
for asthma self-management skills and the provision of
an asthma action plan. Working in close consultation
with each woman’s primary health care provider (i.e. GP)
and hospital-based midwives and specialist physicians, the
respiratory nurse is able to play a key role in guiding opti-
mized asthma management and empowering pregnant
women to manage their asthma more effectively. The
introduction of this intervention has a significant poten-
tial to improve current clinical care of pregnant women
with asthma and lead to a significant reduction in the
incidence and severity of asthma exacerbations, im-
prove asthma control and related quality of life and de-
crease the negative impact of asthma on a range of
Perinatal health outcomes. These improvements in
health outcomes are of major benefit to the health care
system, as there are significant costs associated with
managing exacerbations (i.e. unplanned medical and
emergency department visits, hospitalizations), mater-
nal complications (i.e. pre-eclampsia) and neonatal
complications (i.e. low birth weight) associated with
maternal asthma. In addition to immediate costs, many
of these outcomes are associated with long-term mor-
bidity for the child and adult, representing a substantial
ongoing cost and health burden to society for the entire
life span of these individuals [43].
The data generated from this study will provide strong
evidence in support of new policies for the care of preg-
nant asthmatic women and models of health service de-
livery. A significant benefit of this proposal lies in the
fact that the intervention can be introduced in any set-
ting where pregnant women are cared for, which in-
clude hospitals, GP offices and regional health services.
Furthermore, an established relationship between the
research group and asthma organizations (i.e. Asthma
Australia) will ensure the effective dissemination of the
results and recommendations of this study to clinical
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